Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Vertex said interim data from an open-label extension study in children ages 2 to 5 showed recovery of exocrine pancreatic function in some participants treated with ALYFTREK. The company also presented additional abstracts on CFTR modulators at the North American Cystic Fibrosis Conference.
Vertex Pharmaceuticals said it will present new interim data from its ALYFTREK® 2-to-5-year-old open-label extension study.